16 results about "Serotype a" patented technology

The invention discloses a broad-spectrum avibacterium paragallinarum protective antigen and application thereof, and belongs to the field of prevention and control of poultry infectious diseases. The invention provides an application of an avibacterium paragallinarum protein p1 in preparation of a broad-spectrum avibacterium paragallinarum protective antigen protein. The amino acid sequence of the avibacterium paragallinarum protein p1 is as shown in SEQ ID No. 1. The protective antigen protein has strong immunogenicity and reactogenicity, and a subunit vaccine prepared by using the antigen protein can provide 90% protection rate for avian paragallinarum of three serotypes A, B and C, and can effectively prevent infection of the avian paragallinarum.

The present disclosure relates to methods of producing a 900 kDa BoNT / A complex, wherein the method does not comprise a step of precipitation during the purification process. Further provided herein are methods of preparing a Clostridium botulinum working cell bank (WCB).

Provided herein are compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A) with improved stability. Such BoNT / A compositions are produced by a process comprising filtering a solution comprising BoNT / A with a filter that is not gamma-irradiated or a filter that contains no free radicals or a low amount of free radicals. Further provided herein are methods of producing compositions comprising BoNT / A by filtering a solution comprising BoNT / A with a filter that is not gamma-irradiated or a filter that contains no free radicals or a low amount of free radicals.

The invention discloses a chicken infectious rhinitis trivalent inactivated vaccine and a preparation method thereof, and relates to the technical field of bioengineering. The avibacterium paragallinarum immunoprotective antigen protein provided by the invention is formed by fusion of an immune enhancement sequence and an immunogenic protein HMTp210 of avibacterium paragallinarum. The invention further provides a chicken infectious rhinitis subunit vaccine. Immunoactive components of the chicken infectious rhinitis subunit vaccine comprise the A type avibacterium paragallinarum immunoprotective antigen protein, the B type avibacterium paragallinarum immunoprotective antigen protein and the C type avibacterium paragallinarum immunoprotective antigen protein. The vaccine can obviously enhance the resistance of chickens to three serotypes of avibacterium paragallinarum A, B and C, the safety and the protective effect of the vaccine are superior to those of a whole-cell inactivated vaccine, and the vaccine can be used for preventing chicken infectious rhinitis caused by different serotypes of avibacterium paragallinarum.

Provided herein are solid compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A), human serum albumin (HSA) and sodium chloride (NaCl); wherein less than 34% of soluble HSA conta

Provided herein are solid compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A) and human serum albumin (HSA), wherein the solid compositions comprise a low amount of HSA aggregates. Further provided herein are methods of producing solid compositions comprising BoNT / A and HSA by drying a solution comprising BoNT / A in a manner such that the solution does not undergo freezing during drying.

The present invention belongs to the field of biotechnology, and specifically relates to a mutant of botulinum neurotoxin serotype A (BoNT / A) and its application. Compared with the wild-type BoNT / A having the amino acid sequence shown in SEQ ID NO:1, the mutant has at least one amino acid difference. In view of the defects of the prior art, through the screening of various sequences, the present invention provides an optimized BoNT / A sequence. Through codon optimization of the sequence and partial sequence replacement, not only high-purity soluble expression is achieved, but also the recombinantly expressed BoNT / A can mimic the natural post-translational modification process. Therefore, the optimized BoNT / A sequence provided by the present invention has broad prospects in the industrial production of BoNT / A.

A composition comprising a Clostridium botulinum neurotoxin serotype A (BoNT / A) complex comprising a plurality of variant species, wherein the variant species comprises BoNT / A with a C-terminal trunca

The present invention belongs to the field of chemistry. Disclosed in the present invention is a method for the chemical synthesis of a Vibrio vulnificus biotype 2 serotype A O-antigen disaccharide fragment. In the present invention, D-glucose, L-galactose, etc. are used as raw materials to prepare two glycosylated building blocks, and a set of synthesis routes for efficiently constructing a disaccharide fragment is designed. By means of the optimization of a protecting group and the timing for introducing a modification group, the target disaccharide is successfully prepared. The disaccharide prepared in the present invention has easily obtainable raw materials, and a simple and easily repeatable preparation method, and has good application prospects in the aspects such as the development of new drugs and vaccines for Vibrio vulnificus.

Provided herein are compositions comprising a Clostridium botulinum neurotoxin serotype A (BoNT / A) complex comprising a 150 kDa BoNT / A. Said 150 kDa BoNT / A is in the form of a plurality of sequence variant species, wherein the plurality of sequence variant species comprises a 150 kDa BoNT / A sequence variant species with a C-terminal truncated light chain.

Provided herein are Haemophilus influenzae saccharide-carrier conjugates and compositions thereof. Also provided are methods of making and using the conjugates and compositions thereof, and kits containing the conjugates. Haemophilus influenzae saccharide-lipid conjugates, Haemophilus influenzae saccharide-glycosphingolipid conjugates, compositions containing these, methods of making and using the conjugates and compositions, and kits containing these, are also disclosed. Saccharide-lipid conjugates, and saccharide-glycosphingolipid conjugates comprising saccharides from Haemophilus influenzae serotype a, as well as compositions containing these, methods of making and using the conjugates and compositions, and kits containing these, are also disclosed.

The present disclosure relates to methods for preparing Clostridium botulinum working cell bank. Further provided herein are methods of producing a composition comprising a 900 kDa BoNT / A complex, said method comprising an acid precipitation step.

Provided herein are solid compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A) and human serum albumin (HSA), wherein the solid compositions comprise a small amount of HSA aggregates. Further provided herein are methods for preparing solid compositions comprising BoNT / A and HSA by drying a BoNT / A-containing solution such that the solution does not freeze during drying.

Provided herein are solid compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A) and human serum albumin (HSA), wherein the solid compositions comprise a low amount of HSA aggregates. Further provided herein are methods of producing solid compositions comprising BoNT / A and HSA by drying a solution comprising BoNT / A in a manner such that the solution does not undergo freezing during drying.

Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

The present invention relates to solid compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A) and human serum albumin (HSA), wherein the solid compositions comprise a small amount of HSA aggregates. The present invention further relates to methods of producing solid compositions comprising BoNT / A and HSA by drying a solution comprising BoNT / A such that the solution does not undergo freezing upon drying. Figure for abstract: 2A